Filings & corporate actions
78 results filed
CSVNext results · Q2 FY27
Expected 30 Oct 2026 – 11 Nov 2026
Estimate: filed 30–42 days after quarter end, last 5 times
Dividend
₹57.00 per share · last 29 May 2026
2026
- 3 AugresultsResults · Q1 FY27 · consolidated and standalone-0.6%NSE
- 16 JulshareholdingShareholding · 30 Jun 2026+0.9%NSE
- 29 MaydividendDividend · ₹57.00 per share-3.7%
- 13 MayresultsResults · Q4 FY26 · consolidated and standalone+0.2%NSE
- 10 AprshareholdingShareholding · 31 Mar 2026+1.5%NSE
- 9 FebresultsResults · Q3 FY26 · consolidated and standalone+4.2%NSE
- 9 JanshareholdingShareholding · 31 Dec 2025-1.1%NSE
Reaction to results · all yearsrose on day 0 in 38 of 77 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 3 Aug 2026 | -0.6% | -2.3% | +12.5% | 1.3× |
| Q4 FY26 | 13 May 2026 | +0.2% | -3.8% | -12.0% | 0.7× |
| Q3 FY26 | 9 Feb 2026 | +4.2% | +3.5% | -1.2% | 5.2× |
| Q2 FY26 | 6 Nov 2025 | -0.7% | -4.8% | -2.3% | 2.9× |
| Q1 FY26 | 1 Aug 2025 | -2.3% | -8.5% | -5.4% | 1.9× |
| Q4 FY25 | 13 May 2025 | +3.2% | +7.0% | +21.1% | 2.8× |
| Q3 FY25 | 14 Feb 2025 | +16.0% | +30.7% | +40.6% | 9.2× |
| Q2 FY25 | 30 Oct 2024 | +1.7% | 0.0% | -7.0% | 1.8× |
| Q1 FY25 | 2 Aug 2024 | -2.0% | +2.5% | +0.4% | 1.0× |
| Q4 FY24 | 17 May 2024 | +3.2% | +3.2% | +15.6% | 0.7× |
| Q3 FY24 | 12 Feb 2024 | -6.9% | -2.2% | -14.5% | 2.9× |
| Q2 FY24 | 9 Nov 2023 | +1.5% | +8.8% | +15.9% | 3.1× |
| Q1 FY24 | 27 Jul 2023 | -0.1% | +0.1% | +1.4% | 0.8× |
| Q4 FY23 | 18 May 2023 | -1.1% | +0.7% | +8.2% | 1.9× |
| Q3 FY23 | 8 Feb 2023 | +3.1% | +0.8% | +4.5% | 4.3× |
| Q2 FY23 | 11 Nov 2022 | +0.9% | -1.3% | +0.4% | 0.7× |
| Q1 FY23 | 25 Jul 2022 | -2.3% | -5.4% | -1.2% | 1.9× |
| Q4 FY22 | 17 May 2022 | +0.4% | +2.6% | +1.3% | 5.3× |
| Q3 FY22 | 7 Feb 2022 | -1.9% | -0.5% | -1.5% | 1.4× |
| Q2 FY22 | 30 Oct 2021 | +6.2% | +7.0% | +11.1% | 7.4× |
| Q1 FY22 | 26 Jul 2021 | -3.1% | -2.6% | -11.9% | 2.1× |
| Q4 FY21 | 19 May 2021 | -1.5% | -3.5% | +3.4% | 1.7× |
| Q3 FY21 | 5 Feb 2021 | +2.1% | +0.2% | +6.3% | 6.7× |
| Q2 FY21 | 31 Oct 2020 | -3.8% | -3.8% | +5.9% | 0.5× |
| Q1 FY21 | 30 Jul 2020 | -2.6% | -0.2% | +8.0% | 1.8× |
| Q4 FY20 | 19 May 2020 | +1.7% | -0.5% | +2.0% | 1.1× |
| Q3 FY20 | 4 Feb 2020 | -12.1% | -19.7% | -20.5% | 4.1× |
| Q2 FY20 | 23 Oct 2019 | +0.5% | +12.3% | +10.8% | 1.4× |
| Q1 FY20 | 23 Jul 2019 | +1.1% | +0.9% | +1.5% | 2.1× |
| Q4 FY19 | 21 May 2019 | -0.3% | -0.1% | -2.7% | 1.2× |
| Q3 FY19 | 11 Feb 2019 | -0.8% | -2.8% | -5.3% | 0.9× |
| Q2 FY19 | 24 Oct 2018 | -2.5% | +8.2% | +3.1% | 0.8× |
| Q1 FY19 | 2 Aug 2018 | +3.2% | +3.0% | +7.9% | 1.9× |
| Q4 FY18 | 22 Jun 2018 | -0.8% | -0.1% | -1.0% | 0.5× |
| Q3 FY18 | 14 Feb 2018 | +0.4% | -2.5% | -6.4% | 0.8× |
| Q2 FY18 | 31 Oct 2017 | +1.2% | +3.9% | -3.5% | 1.6× |
| Q1 FY18 | 2 Aug 2017 | -0.3% | +0.3% | +2.6% | 0.6× |
| Q4 FY17 | 23 May 2017 | -0.3% | -1.6% | +1.6% | 0.8× |
| Q3 FY17 | 14 Feb 2017 | -0.1% | -0.6% | +2.3% | 0.7× |
| Q2 FY17 | 8 Nov 2016 | -2.3% | -4.2% | -1.9% | 2.3× |
| Q1 FY17 | 30 Sept 2016 | -0.9% | +4.0% | +1.7% | 0.9× |
| Q4 FY16 | 26 May 2016 | +2.0% | +2.8% | -0.6% | 1.7× |
| Q3 FY16 | 19 Feb 2016 | +0.6% | -1.8% | +7.9% | 0.5× |
| Q2 FY16 | 2 Nov 2015 | -2.1% | -2.4% | -0.1% | 3.1× |
| Q1 FY16 | 3 Aug 2015 | +2.0% | +2.7% | -3.6% | 2.1× |
| Q3 FY15 | 18 Feb 2015 | -0.1% | -4.4% | +0.9% | 0.3× |
| Q2 FY15 | 11 Nov 2014 | -1.2% | +1.8% | +12.8% | 1.4× |
| Q1 FY15 | 19 Aug 2014 | +0.1% | -0.3% | +0.6% | 0.7× |
| Q4 FY14 | 21 Apr 2014 | -0.1% | -2.5% | +2.3% | 0.8× |
| Q3 FY14 | 20 Feb 2014 | +0.4% | +1.2% | -15.4% | 0.9× |
| Q2 FY14 | 21 Nov 2013 | 0.0% | +3.7% | +21.8% | 0.4× |
| Q1 FY14 | 12 Aug 2013 | -2.0% | -4.0% | +3.6% | 0.4× |
| Q4 FY13 | 8 May 2013 | -1.5% | -1.7% | +14.4% | 0.7× |
| Q3 FY13 | 19 Feb 2013 | +0.5% | 0.0% | +2.6% | 0.4× |
| Q2 FY13 | 9 Nov 2012 | +0.3% | -0.3% | +2.2% | 2.9× |
| Q1 FY13 | 13 Aug 2012 | -0.4% | -0.9% | +5.5% | 0.9× |
| Q4 FY12 | 7 May 2012 | -1.3% | -4.6% | -5.5% | 1.4× |
| Q2 FY12 | 4 Nov 2011 | -3.2% | -6.2% | -10.1% | 0.9× |
| Q1 FY12 | 11 Aug 2011 | +1.9% | +1.3% | -2.8% | 4.2× |
| Q4 FY11 | 6 May 2011 | +1.7% | +3.7% | +6.2% | 1.9× |
| Q3 FY11 | 14 Feb 2011 | -0.6% | +0.9% | -5.8% | 0.4× |
| Q2 FY11 | 28 Oct 2010 | -0.1% | -1.6% | -6.8% | 3.1× |
| Q1 FY11 | 26 Jul 2010 | -0.6% | -3.0% | -5.1% | 1.7× |
| Q4 FY10 | 27 Apr 2010 | +0.6% | +3.2% | +6.5% | 0.4× |
| Q3 FY10 | 15 Feb 2010 | 0.0% | +6.4% | +7.5% | 1.5× |
| Q2 FY10 | 30 Oct 2009 | -2.2% | -1.1% | +4.0% | 0.6× |
| Q1 FY10 | 27 Jul 2009 | +0.6% | +2.6% | +4.4% | 1.1× |
| Q4 FY09 | 28 Apr 2009 | +1.0% | 0.0% | +0.2% | 1.2× |
| Q3 FY09 | 18 Feb 2009 | +0.6% | -1.0% | -12.7% | 4.4× |
| Q2 FY09 | 24 Oct 2008 | +2.2% | +9.3% | +17.2% | 2.2× |
| Q1 FY09 | 28 Jul 2008 | +1.2% | +2.7% | +5.0% | 1.5× |
| Q4 FY08 | 21 Apr 2008 | +1.0% | +1.3% | +8.7% | 0.8× |
| Q3 FY08 | 22 Feb 2008 | +2.4% | +19.3% | +5.4% | 0.7× |
| Q2 FY08 | 25 Oct 2007 | +0.4% | -1.9% | -3.6% | 0.4× |
| Q1 FY08 | 26 Jul 2007 | -2.5% | -7.1% | -11.3% | 1.1× |
| Q4 FY07 | 27 Apr 2007 | +0.8% | +2.0% | +8.6% | 0.9× |
| Q3 FY07 | 16 Feb 2007 | +1.4% | +4.2% | +2.4% | 1.1× |
| Average | +0.1% | +0.7% | +2.1% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+16.6%
Profit YoY+15.7%
Interest cost YoY+141.2%
Revenue QoQ-5.7%
Profit QoQ-14.6%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +6.2% | +6.6% | — | +3.4% | +4.2% | — |
| Profit | +29.2% | +19.6% | — | +23.7% | +50.9% | — |
Key data
CSVOpen2,738.80
Day range2,707.00 – 2,762.90
52-week range2,088.10 – 3,120.70
From 52w high-11.7%
RSI (14)42.6
ATR (14)83.01
Volume39.2K
Avg volume (20D)77.2K
Rel volume0.51×
Volatility (1Y)25.3%
Turnover₹10.8Cr
SMA 50 / 2002,811.03 / 2,512.50
Delivery percentage
Latest · 6 Oct 202648.5%
20-day avg49.6%
1-year avg57.4%
Percentile (own history)23rd
Range8.4–96.6%
Sessions1,731
Over the last 20 sessions GLAXO settled 49.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 57.4%, so recent sessions are running 7.8 points lower than usual. The latest session ranks higher than 23% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.81% | -4.88% | -6.21% | +14.48% | +19.19% | +3.09% |
Valuation
CSVMarket cap₹46,671 Cr
P/E (TTM)43.7
EPS (TTM)63.05
Shares outstanding16.94Cr
Listed15 Dec 2000
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 979.9 | 1,041.3 | 995.3 | 938.4 |
| YoY chg | -3.1% | +9.7% | +2.1% | +16.6% |
| Net profit (₹ Cr) | 257.5 | 295.6 | 277.9 | 237.2 |
| YoY chg | +2.0% | +28.6% | +5.7% | +15.7% |
| Net margin | 26.3% | 28.4% | 27.9% | 25.3% |
| EPS | 15.20 | 17.45 | 16.40 | 14.00 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 75.00% · public 25.00%2021-092026-06
- Promoter
- Public and others
- Promoter
- 75.00%
- Public
- 25.00%
- Promoter change
- 0.00 pp
- Filed
- 16 Jul 2026
- FII
- 4.79%
- DII
- 7.80%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 957.0 | 805.3 | 929.8 | 814.7 | 1,010.8 | 949.4 | 974.4 | 805.2 | 979.9 | 1,041.3 | 995.3 | 938.4 | |
| Other income | 28.2 | 28.1 | 29.8 | 35.6 | 34.5 | 35.1 | 40.7 | 43.7 | 33.6 | 32.1 | 36.0 | 43.8 | |
| Total income | 985.2 | 833.4 | 959.6 | 850.3 | 1,045.3 | 984.5 | 1,015.1 | 848.9 | 1,013.5 | 1,073.4 | 1,031.3 | 982.2 | |
| Total expenses | 686.0 | 604.6 | 691.4 | 600.9 | 706.2 | 676.4 | 656.5 | 569.9 | 662.2 | 691.4 | 658.2 | 659.8 | |
| └ Finance costs | 0.4 | 0.3 | 0.8 | 0.4 | 0.3 | 0.1 | 0.6 | 0.4 | 0.5 | 1.2 | 0.6 | 1.0 | |
| └ Depreciation | 18.1 | 17.1 | 18.1 | 16.4 | 16.9 | 18.8 | 14.7 | 15.5 | 17.4 | 20.3 | 13.2 | 15.8 | |
| Profit before tax | 299.2 | 65.4 | 270.6 | 249.4 | 343.8 | 308.1 | 358.6 | 279.0 | 354.0 | 399.9 | 373.1 | 322.5 | |
| Tax expense | 81.7 | 19.7 | 76.1 | 67.1 | 91.3 | 78.2 | 95.7 | 74.0 | 96.5 | 104.3 | 95.2 | 85.3 | |
| Net profit | 217.5 | 45.7 | 194.5 | 182.3 | 252.5 | 229.9 | 262.9 | 205.0 | 257.5 | 295.6 | 277.9 | 237.2 | |
| EPS | 12.84 | 9.89 | 11.48 | 10.76 | 14.67 | 13.57 | 15.52 | 12.10 | 15.07 | 16.54 | 16.40 | 14.00 | |
| Net margin | 22.73% | 5.68% | 20.92% | 22.38% | 24.98% | 24.21% | 26.98% | 25.46% | 26.28% | 28.39% | 27.92% | 25.27% | |
| PBT margin | 31.26% | 8.13% | 29.11% | 30.61% | 34.01% | 32.45% | 36.80% | 34.65% | 36.12% | 38.41% | 37.49% | 34.36% | |
| Tax rate | 27.29% | 30.12% | 28.14% | 26.89% | 26.56% | 25.39% | 26.69% | 26.51% | 27.26% | 26.08% | 25.53% | 26.44% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 3 Aug 2026.
GLAXO at a glance
- GLAXO closed at ₹2,755 on 6 Oct 2026, +0.81% on the day, +3.1% over one year, 11.7% below its 52-week high of ₹3,120.7.
- Delivery was 48.5% of traded quantity on 6 Oct 2026, the 23rd percentile of its own 1,731 sessions with a reading (20-session average 49.6%, 1-year average 57.4%).
- Market capitalisation is ₹46,671 crore at a trailing P/E of 43.7 (trailing EPS ₹63.05).
- Q1 FY27 results (consolidated, filed 3 Aug 2026): revenue ₹938 crore (+16.6% year on year), net profit ₹237 crore (+15.7%); the price moved -0.6% on the first session after.
- Promoters held 75.00% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 30 Oct 2026 and 11 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE159A01016
SeriesEQ
Listed15 Dec 2000
History from2 Jan 1995
Sessions7,852
Turnover rank#739
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE